Rani Therapeutics Holdings, Inc. (RANI)
$1.95
Rating:
Recommendation:
-
| Symbol | RANI |
|---|---|
| Price | $1.95 |
| Beta | 0.334 |
| Volume Avg. | 0.04M |
| Market Cap | 103.426M |
| Shares () | - |
| 52 Week Range | 1.8901-10.743 |
| 1y Target Est | - |
| DCF Unlevered | RANI DCF -> | |
|---|---|---|
| DCF Levered | RANI LDCF -> | |
| ROE | -153.07% | Strong Sell |
| ROA | -61.34% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 126.42% | Buy |
| P/E | -1.52 | Sell |
| P/B | 2.05 | Strong Buy |
Latest RANI news
About
Download (Excel)Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.